AKEBIA THERAPEUTICS INC (AKBA)
Health Care · Kidney disease therapeutics · NASDAQ
A biopharmaceutical company specialized in kidney disease therapeutics with a commercial portfolio for anemia and mineral metabolism and a pipeline of rare disease assets.
What AKEBIA THERAPEUTICS INC does
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on developing and commercializing innovative therapeutics for kidney disease. The company markets two commercial products: Vafseo® (vadadustat), an oral HIF-based treatment for anemia in dialysis patients launched in January 2025, and Auryxia® (ferric citrate), an oral medicine for serum phosphorus control and iron deficiency anemia in CKD patients. The company also maintains a pipeline of mid-stage and early-stage programs targeting rare kidney diseases and broader kidney-related indications.
Themes: Kidney disease / nephrology, Dialysis management, Chronic kidney disease (CKD), Rare kidney diseases, HIF pathway / erythropoiesis, Complement inhibition
Fundamentals
- Price$0.907 as of 2026-08-21 close
- Market cap$251M as of 2026-08-21
- 1-year return-71.6% 2025-08-21 close $3.19 → 2026-08-21 close $0.907
- P/En/a negative earnings
- Net margin-13.5% as of 2026-08-24
- Gross margin+81.5% as of 2026-08-24
- ROE-93.7% as of 2026-08-24
- Debt / equity7.69 as of 2026-08-24
- Revenue growth (YoY)+7.5% as of 2026-08-24
- Revenue CAGR (3y)-6.9% SEC XBRL
- Beta0.20 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How AKBA compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How AKEBIA THERAPEUTICS INC looks technically
AKEBIA THERAPEUTICS INC (AKBA) is trading 33.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 194 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 10 trading days ago. It is 72.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 33.0% below its 200-day average, the long-term trend line — a long-term downtrend | -33.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.14 | $1.14 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.35 | $1.35 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 22 calendar days ago — the swings before that are what the structure reading is measured on | 22 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 1.36. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 194 trading days ago — a "death cross", a bearish long-term signal | 194 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with sellers in control | 31.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 35.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($0.8147 to $1.35) — its "stochastic" reading is 17 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 17.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 24 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.32 | $3.32 |
|---|---|---|
| From the 52-week high | it is 72.7% below its 52-week high (its highest price of the past year) | -72.7% |
| Above the 52-week low | it is 11.3% above its 52-week low (its lowest price of the past year) | +11.3% |
| Below the 52-week high | it is 72.7% below its highest point of the past year | 72.7% |
| Since a 20-day breakout | it made a new 20-day low about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day low about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $31.00 (set on 2014-06-20) | $31.00 |
| Given back of the 52-week move | over the past year its closes ranged ($0.844 to $3.19), and it has recovered only a small part of its fall from last year’s high — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.29 to $2.37. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 2.7% |
| From the all-time high | it is 97.1% below its all-time high | -97.1% |
| Nearest price level | it is trading 30.6% below a resistance level at $1.19 — a price it turned at twice since 2026-03-05, most recently on 2026-07-23. Since 2024-08-21 it has 0 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +30.6% |
| All-time low | its lowest closing price on record is $0.241 (set on 2022-10-24) | $0.241 |
| Above the all-time low | it is 276.3% above its all-time low | +276.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0718 between its high and its low — about 7.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0718 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.64 and $1.46 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.64 – $1.05 – $1.46 |
| Typical daily range (% of price) | its price moves about 7.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.9% |
| Stretch from the 200-day average | it is trading 6.2 daily ranges below its 200-day average price (33.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.50× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 9.5% since the prior reading | -9.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.40 toward sell |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.6% |
|---|---|---|
| Open gap | it gapped 30.1% below the previous close 11 sessions ago and has not traded back through the level it left behind at 1.29 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -30.1% |
| Gap filled | a 2.4% gap down opened on 2026-07-23 has been "filled" 19 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 19 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 32.6 percentage points (the stock lost 30.2% while the market gained 2.3%) | -32.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 14.2 percentage points (the stock lost 11.1% while the market gained 3.1%) | -14.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 34.2 percentage points (the stock lost 23.1% while the market gained 11.1%) | -34.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 92.0 percentage points (the stock lost 71.6% while the market gained 20.5%) | -92.0% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 24% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.7% of the share price. | -23.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 24% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.19 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -23.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $0.9208 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -1.5% |
Price levels it has turned at before
AKBA last closed at $0.907 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 14 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.19 | Resistance | 30.6% above the last close | turned there twice · 2026-03-05 to 2026-07-23 |
| $1.25 | Resistance | 37.5% above the last close | turned there twice · 2024-10-01 to 2024-10-10 |
| $1.27 | Resistance | 40.6% above the last close | turned there twice · 2024-09-04 to 2024-09-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $1.36.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Analyst price target recently CUT · lagging the market · Most volatile (6%+ typical daily range) · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.60 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$3.80 range $1.00 – $6.00; median $4.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AKBA
- Consensus EPS estimate-$0.04 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Auryxia loss of exclusivity in March 2025 with generic competition from Teva and additional generics expected throughout 2026, creating significant revenue headwind for a historically meaningful product","Vafseo commercial uptake dependent on dialysis organization adoption and prescriber protocol implementation; currently only ~290,000 of estimated dialysis patients have prescribing access","Company is unprofitable with negative net margin of -8.83% and relies on continued commercial success of Vafseo and pipeline development to achieve profitability despite 25.69% revenue growth"]
What changed in the latest 10-Q
AI-assisted comparison of AKBA's 10-Q filed 2026-05-07 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) references 2025 Form 10-K filed February 26, 2026, replacing older filing's reference to 2024 Form 10-K filed March 13, 2025
- Newer filing adds specific language about contributing net product revenue to support pipeline development
- Newer filing updates CKD patient impact to 'approximately 35.5 million patients' with specific 2022 U.S. Medicare costs ($95.7 billion for CKD, $45.3 billion for dialysis)
- Newer filing specifies Vafseo market opportunity as 'approximately $1 billion' based on current ESA pricing (moved from general statement)
- Newer filing adds 'approximately 290,000 dialysis patients in the U.S. have prescribing access to Vafseo' (new quantification)
- Newer filing notes Vafseo approved in 37 countries
- Newer filing specifies Auryxia LoE date as March 2025 with Teva ANDA approval on March 11, 2026 and generic market entry detail
- Newer filing introduces praliciguat Phase 2 clinical trial with first patient dosed December 2025
- Newer filing adds Q32 Bio asset purchase agreement (November 2025) for AKB-097 (ebribafusp), an anti-C3d-Factor H fusion protein complement inhibitor
- Newer filing specifies planned Phase 2 basket study for AKB-097 in second half of 2026 for IgAN, C3G, and LN indications
- Newer filing describes AKB-9090 first patient dosed in Phase 1 study in April 2026
- Newer filing adds AKB-10108 description as HIF molecule in preclinical development
- Newer filing adds language about exploring additional commercial and development opportunities through internal research and external innovation
- Removed:
- Older filing's statement about HIF science expertise and 'selected two additional HIF-based molecules for preclinical development' is removed from opening paragraph in newer filing
- Older filing's reference to 'approximately 37 million patients' affected by CKD is replaced with 35.5 million in newer filing
- Older filing's reference to Medicare cost of 'nearly $125 billion annually' is replaced with specific 2022 figures in newer filing
- Older filing's discussion of Type C meeting with FDA regarding VALOR clinical trial for non-dialysis CKD patients is removed from newer filing
- Older filing's statement that 'we do not plan to initiate VALOR and therefore do not expect to pursue a broad label for Vafseo' is removed from newer filing
- Older filing's international commercialization details for Vafseo (MEDICE, MTPC, Tai Tien, Korea) are removed from newer filing
- Older filing's extended discussion of Auryxia international partnerships (JT/Torii in Japan, Averoa in EEA) and European regulatory progress is removed from newer filing
- Older filing's discussion of Auryxia reimbursement in ESRD bundle affecting revenue decline is removed from newer filing
- Older filing's general statement about praliciguat being 'an investigational oral solu[ble guanylate cyclase stimulator]' without trial details is replaced with specific Phase 2 FSGS trial information in newer filing
- Reworded:
- Newer filing changes 'serves as a foundation' to 'serve as a foundation' (grammatical tense shift)
- Newer filing removes detailed HIF science background from opening and replaces with more focused business description
- Newer filing changes 'kidney community' reference and removes extensive discussion of HIF discovery's role in oxygen sensing
- Newer filing describes Vafseo as 'orally administered' without 'HIF factor prolyl hydroxylase inhibitor' technical descriptor in opening section
- Older filing states 'Shipment of Vafseo commenced in January 2025' while newer filing states 'Vafseo entered the market in January 2025'
- Newer filing changes 'loss of exclusivity' description with actual Teva generic approval date and market entry detail
- Older filing discusses praliciguat licensing in general terms; newer filing provides Phase 2 trial status and timeline
- Newer filing adds 'rare' descriptor to mid-stage kidney disease pipeline assets characterization
- Notes:
- Older filing appears to be truncated at end of praliciguat section; full comparison of this section not possible
- Newer filing is also truncated at end of Product Revenue section discussing Auryxia patent exclusivity; full comparison of this section not possible
- International regulatory and partnership details present in older filing but largely absent in newer filing—unclear if removal reflects de-emphasis or mere section reorganization not shown in excerpt
Risk Factors
- Added:
- Newer filing specifies net loss of $9.1 million for the three months ended March 31, 2026 (filed 2026-05-07)
- Newer filing adds reference to 'the receipt of a complete response letter, or CRL, from the FDA in March 2022' in the paragraph about Vafseo approval (filed 2026-05-07)
- Newer filing adds 'the availability and pricing of generic versions of Auryxia' as a separate factor in the bullet point about generic competition (filed 2026-05-07)
- Removed:
- Older filing references net income of $0.5 million and $6.9 million for the three and nine months ended September 30, 2025, removed in newer filing (filed 2025-11-10)
- Older filing states sufficient cash resources to fund 'the foreseeable future' whereas newer filing states 'for at least two years' (filed 2026-05-07)
- Older filing contains detailed explanation of CRL receipt in March 2022 and FDRR process in 2022 and NDA resubmission in 2023, condensed in newer filing (filed 2025-11-10)
- Reworded:
- Older: 'sufficient to fund our current operating plan for the foreseeable future' changed to 'sufficient to fund our current operating plan for at least two years' (filed 2026-05-07)
- Older: 'the pricing of generic versions of Auryxia' changed to 'the availability and pricing of generic versions of Auryxia' (filed 2026-05-07)
- Older: 'the impact of the LoE on the product revenue' changed to 'the impact of LoE on the product revenue' (filed 2026-05-07)
- FDA approval narrative reorganized: older filing detailed CRL, FDRR, and resubmission process; newer filing references CRL in March 2022 within the approval paragraph more concisely (filed 2026-05-07)
- Notes:
- Older filing text appears truncated at end; comparison limited to complete sections available
- Dates reference reporting periods (March 31, 2026 vs. September 30, 2025) which naturally differ between quarterly filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($62181) — 1 selling insider
- Last 180 days1 buy ($86588) · 1 sell ($62181) — 1 buying, 1 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-29. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AKBA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AKBA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 35,202,125
- Reported value $48,930,956
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AKBA had 19,183,020 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AKBA had 6.92% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.81 days to cover at the same settlement.
- Reported short interest (shares) 19,183,020
- Short interest (% of shares outstanding) 6.92%
- Prior settlement (shares) 19,076,806
- Reported change 0.56%
- Days to cover (reported) 8.81
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Fresenius Medical Care
- Teva Pharmaceuticals (TEVA)
- GSK (formerly ViiV Healthcare)
- FibroGen
- Dialysis organizations
- Dialysis patients
- CKD patients (dialysis-dependent and non-dialysis-dependent)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AKBA vs…
Frequently asked questions
What does AKEBIA THERAPEUTICS INC (AKBA) do?
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on developing and commercializing innovative therapeutics for kidney disease. The company markets two commercial products: Vafseo® (vadadustat), an oral HIF-based treatment for anemia in dialysis patients launched in January 2025, and Auryxia® (ferric citrate), an oral medicine for serum phosphorus control and iron deficiency anemia in CKD patients.
What sector is AKEBIA THERAPEUTICS INC (AKBA) in?
AKEBIA THERAPEUTICS INC (AKBA) is classified in the Health Care sector. Its industry is Kidney disease therapeutics. It trades on NASDAQ.
Who are AKEBIA THERAPEUTICS INC's (AKBA) competitors?
Notable peers of AKEBIA THERAPEUTICS INC (AKBA) include Amgen, Fresenius Medical Care, Teva Pharmaceuticals, GSK (formerly ViiV Healthcare) and FibroGen. This peer set is informational only — not financial advice.
Is AKEBIA THERAPEUTICS INC (AKBA) overbought or oversold right now?
AKEBIA THERAPEUTICS INC (AKBA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AKBA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.